SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Share Price rises 5.48% to Rs 1,104.15
- September 18, 2026
- Posted by: Harsh Piplani
- Category: News
SYMBIOTEC Share Price is in focus after the stock rose 5.48% to Rs 1,104.15 on 18 September 2026 at 2:18:44 PM IST. The move added Rs 57.35 to the previous close of Rs 1,046.80 and took the company’s market capitalisation to Rs 6,698.70 Cr. The day’s range shows an open at Rs 1,050, a low of Rs 1,047.65 and a high of Rs 1,104.15, which also matches the current price.
This SYMBIOTEC Share Price update confirms a clear same-day price rise, but the supplied data does not establish a company-specific catalyst. For readers tracking SYMBIOTEC Stock News, the important points today are the exact price move, turnover of Rs 6.78 Cr and the valuation backdrop. Univest is following the stock because the move comes with a premium multiple in a healthcare business that can be compared against its pharmaceutical peers. Investors looking at SYMBIOTEC Share Price Today can use the session data, fundamentals and sector benchmark below to frame the move in a broader market context.
SYMBIOTEC Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,104.15 |
| Previous Close | Rs 1,046.8 |
| Today's Move | Rs 57.35 (+5.48%) |
| Open | Rs 1,050 |
| High | Rs 1,104.15 |
| Low | Rs 1,047.65 |
| Turnover | Rs 6.78 crore |
| Market Capitalisation | Rs 6,698.7 crore |
| Market Cap Category | Mid Cap |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) rose to Rs 1,104.15 from the previous close of Rs 1,046.8, a move of Rs 57.35 or 5.48%. The stock opened at Rs 1,050, reached a high of Rs 1,104.15, recorded a low of Rs 1,047.65.
SYMBIOTEC Share Price Today shows a straightforward gain of 5.48% after opening at Rs 1,050 and moving to an intraday high of Rs 1,104.15. The stock closed the session’s measured move at the same level as the high, while the low was Rs 1,047.65. Compared with the previous close of Rs 1,046.80, the stock added Rs 57.35 in value. Turnover stood at Rs 6.78 Cr, which is the only traded-value metric supplied for the session. On this data alone, SYMBIOTEC Stock Gaining Today can be described as a price rise day, without attaching any unverified reason or catalyst.
From a market-news perspective, this is the kind of SYMBIOTEC Share Price News that attracts attention in the Indian stock market because it combines a positive daily change with a move to the day’s highest point. Univest will continue to present such stock updates in a structured way so readers can compare the day’s move with the company’s valuation and sector position.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 6,698.7 crore |
| P/E Ratio | 61.2x |
| P/B Ratio | 4.53x |
| ROE | 11.22% |
| ROCE | 12.41% |
| EPS | Rs 17.1 |
| Book Value Per Share | Rs 231.19 |
| Dividend Yield | 0% |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 61.2x, P/B 4.53x, ROE 11.22%, ROCE 12.41%. These figures provide context only and are not a buy or sell signal.
SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 6698.7 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 61.2x, P/B at 4.53x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 17.1, book value per share of Rs 231.19, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.69x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 61.2x |
| Benchmark Median P/E | 32.69x |
| Benchmark Average P/E | 44.72x |
| Benchmark P/E Range | 3.44x to 417.17x |
| Company P/B Ratio | 4.53x |
| Benchmark Median P/B | 3.1x |
| Company ROE | 11.22% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 12.41% |
| Benchmark Median ROCE | 13.65% |
| Company Market Capitalisation | Rs 6,698.7 crore |
| Benchmark Median Market Cap | Rs 741.38 crore |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 61.2x, which is above the benchmark median of 32.69x, a difference of +87.21%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.78%, a difference of -4.75%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.65%, a difference of -9.08%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,44,716.74 | 37.01 | 5.18 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,44,223.13 | 84.83 | 14.05 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,83,453.32 | 85.3 | 20.73 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,10,224.17 | 25.14 | 4.21 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,09,848.55 | 32.89 | 3.15 | 11.83 | 16 |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 61.2x compared with the displayed peer median of 37.01x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.22% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 6,698.7 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching SYMBIOTEC
- SYMBIOTEC Share Price rose 5.48% to Rs 1,104.15 in today’s session.
- The stock added Rs 57.35 versus the previous close of Rs 1,046.80.
- Market capitalisation stands at Rs 6,698.70 Cr, and turnover was Rs 6.78 Cr.
- P/E of 61.2 is above the industry median of 32.69 and average of 44.72.
- ROE is 11.22% and ROCE is 12.41%, both useful for SYMBIOTEC Fundamental Analysis.
About SYMBIOTEC
SYMBIOTEC PHARMALAB LTD operates in Healthcare and the Pharmaceuticals & Drugs industry. The company’s market data supplied here shows it as a listed pharmaceutical name with a market capitalisation of Rs 6,698.70 Cr, along with valuation and return ratios that place it within a broader industry comparison set. For readers following SYMBIOTEC Stock News, the business context matters because pharmaceutical companies are often assessed through earnings quality, balance-sheet value and profitability metrics rather than just a single day’s price change.
From the figures available in this update, the company’s current EPS is Rs 17.1, book value is Rs 231.19 and dividend yield is 0. These numbers help form a basic Company Overview for SYMBIOTEC Share Price readers who want to understand the stock beyond the day’s market move. Univest presents the data so investors can connect the price action with the business and industry context.
Track SYMBIOTEC Share Price on Univest
Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
For users searching SYMBIOTEC Share Price Today, SYMBIOTEC Latest News or SYMBIOTEC Stock Analysis, Univest keeps the data organised in one place. That makes it easier to review the stock’s movement, compare it with sector peers and follow the company’s market cap and earnings profile without losing sight of the verified numbers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did SYMBIOTEC Share Price rise today?
Ans. SYMBIOTEC Share Price rose 5.48% to Rs 1,104.15 today, but the supplied data does not establish a company-specific catalyst. The move is confirmed by the session’s price data, previous close and intraday range.
What is SYMBIOTEC Share Price Today?
Ans. SYMBIOTEC Share Price Today is Rs 1,104.15. It is up Rs 57.35 from the previous close of Rs 1,046.80 and finished at the day’s high, based on the supplied market data.
What is the market capitalisation of SYMBIOTEC?
Ans. SYMBIOTEC has a market capitalisation of Rs 6,698.70 Cr. That places the company well above the industry median market cap in the supplied same-industry benchmark of 200 companies. The company operates in the Healthcare sector.
How is SYMBIOTEC valued versus its sector peers?
Ans. SYMBIOTEC trades at 61.2 times earnings and 4.53 times book. That is above the industry median P/E of 32.69 and above peers such as Cipla, Dr. Reddy’s and Zydus Lifesciences.
What do SYMBIOTEC earnings and book value show?
Ans. SYMBIOTEC reports EPS of Rs 17.1 and book value of Rs 231.19 per share. EPS reflects earnings attributable to each share, while book value shows accounting net worth behind each share.
How do ROE and ROCE look for SYMBIOTEC?
Ans. SYMBIOTEC’s ROE is 11.22% and ROCE is 12.41%. ROE is slightly below the industry median of 11.78%, while ROCE is below the benchmark median of 13.65%. ROE stands at 11.22%.
Which peers are relevant for SYMBIOTEC Stock Analysis?
Ans. The supplied peer set includes Sun Pharmaceutical, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Cipla, Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin and Mankind Pharma for relative valuation comparison. Comparable listed companies include Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Torrent Pharmaceuticals.
Should investors track SYMBIOTEC Share Price on Univest?
Ans. Yes, Univest allows readers to track SYMBIOTEC Share Price, company financials, shareholding pattern, 52-week levels and market insights in one place, making it easier to follow the stock’s verified market data.
